| WELCOME TO NADRAC | |
| |
|
| NADRAC MAILING LIST | |
| Please
subscribe to our mailing list to receive important announcements
and Signal issue to your email.
Thank you. |
|
| Downloads | |
| ADR
Report Forms Printable Monthly Newsletter |
|
|
National Adverse Drug Reaction Advisory Committee (NADRAC)
was created in 1994 to ensure safety of drug products and
other therapeutic agent through nationwide postmarketing monitoring
of Adverse Drug Reactions (ADR). It was also established to
provide technical assistance to BFAD in the evaluation of
these reports. NADRAC was composed of a chairperson assisted
by a vice-chair and secretary. All members were appointed
by the Secretary of Health. Representatives were selected
from the academe, clinical sector, and the BFAD itself.
Presently, it is envisioned to go beyond its present functions
to include dissemination of drug related events whether harmful
or beneficial and to provide a venue for interaction with
prescribers of pharmaceutical products.
^---top
In June 30, 1994, then Secretary of Health Dr. Juan Flavier
issued Department order# 345-Is, which created NADRAC.
Its 1st chairman was Dr. Nelia P. Cortes-Maramba of the
Department of Pharmacology, UP College of Medicine. The
10 members were Ms. Virginia O. Barros,Dr. Benjamin Co,Dra.
Liojren Co, Dr. Godofreda Dalmacion, Engr. Rainer Galang,
Dr. Kenneth Hartigan-Go, Mrs. Nazarita T. Lanuza, Dr.
Irma Makalinao, Dr. Isidro Sia and Dra. Madeleine Sumpaico.
August 1994 - Start of Adverse Drug Reaction Monitoring Project involving 2 private tertiary hospitals and one government tertiary hospital. These were Makati Medical Center, University of Santo Tomas Hospita and Philippine General Hospital. Dr. Kenneth Hartigan-Go, Associate Professor Department of Pharmacology UP college of Medicine was the Project leader. February 1995, the program was recognized as National Centre by WHO Collaborating Centre for Drug Monitoring, Upsalla Sweden. 1996, Four Officers from BFAD's Regulations Division I were sent for training in Pharmacovigilance under Dr. K.H-Go at UP College of Medicine. October 1997, ADR Monitoring was institutionized at BFAD and named ADR unit with over 50 participating hospitals. Mrs. Nancy Lanuza was appointed as titular head. The unit was placed under Regulation Diivision 1 which Ms. Lanuza also heads. K.H-Go at UP College of Medicine. NADRAC became advisory to the unit and the Director of the BFAD for drug safety and postmarketing surveillance. Last recorded meeting of NADRAC was December 1997 at the UP College of Medicine Chaired by Dr. Maramba, Present then was Dr. Kintanar, BFAD director. July 2001, Dr Godofreda R. Vergeire-Dalmacion received an appointment from Dr. William D. Torres, Ph. D. to convene NADRAC of which she will head and constitute. October 2002, received funding from WHO through the office of dr. Budiono Santoso to create the NADRAC website. ^---top
Cost effective and rational drug therapy for the Filipino
patients through continuos surveillance of drug products.
^---top 1.
To establish a systematic and prescriber-friendly
reporting system of adverse reactions suspected
to be drug related.
2. To create a database of ADR. 3. To manage a nationwide monitoring system for drug safety 4. To promote proper use of pharmaceutical products. 5. To encourage communication of risk by industry and other stakcholders. 6 . To detect problems with the quality of medicines in the market. 7. To promote rational drug procurement. 8. To create a national database of adr that is linkable to other databases. 9. To collaborate or network with other international monitoring system. ^---top Region
I Dr.
Ma. Mercedes Maat, Davao Medical Center
June 22, 1963 as amended on May
22, 1987
Republic Act 3720 “Food, Drugs and Devices and Cosmetics Act” Creation of Food and Drug Administration now Bureau of Food and Drugs April 20, 1994 BFAD Memorandum Circular No. 5 s. 1994 Submission of ADR reports by pharmaceutical establishments and parties concerned June 30, 1994 Department Order No. 345 - I s. 1994 Creation of National Adverse Drug Reaction Advisory Committee (NADRAC) |